首页> 外文期刊>Drug delivery. >Developments in drug delivery of bioactive alkaloids derived from traditional Chinese medicine
【24h】

Developments in drug delivery of bioactive alkaloids derived from traditional Chinese medicine

机译:中药生物活性生物碱的药物输送研究进展

获取原文
       

摘要

Abstract The bioactive alkaloids (e.g. vincristine, hydroxycamptothecin, ligustrazine, and so on) from traditional Chinese medicine (TCM) have exerted potent efficacies (e.g. anti-tumor, anti-inflammation, immunosuppression, etc.). However, a series of undesirable physicochemical properties (like low solubility and weak stability) and baneful pharmacokinetic (PK) profiles (e.g. low bioavailability, short half time, rapid clearance, etc.) have severely restricted their applications in clinic. In addition, some side effects (like cumulative toxicities caused by high-frequency administration and their own toxicities) have recently been reported and also confined their clinical uses. Therefore, developments in drug delivery of such alkaloids are of significance in improving their drug-like properties and, thus, treatment efficiencies in clinic. Strategies, including (i) specific delivery via liposomes; (ii) sustained delivery via nanoparticles, gels, and emulsions; and (iii) transdermal delivery via ethosomes, solid lipid nanoparticles, and penetrating enhancers, have been reported to improve the pharmacokinetic and physicochemical characters of problematic TCM alkaloids, decline their adverse effects, and thus, boost their curative efficacies. In this review, the recent reports in this field were comprehensively summarized with the aim of providing an informative reference for relevant readers.
机译:摘要中药(TCM)的生物活性生物碱(例如长春新碱,羟基喜树碱,川azine嗪等)发挥了有效的功效(例如抗肿瘤,抗发炎,免疫抑制等)。然而,一系列不良的理化性质(如低溶解度和较弱的稳定性)和有害的药代动力学(PK)特征(如生物利用度低,半衰期短,清除快等)严重限制了它们在临床中的应用。另外,最近已经报道了一些副作用(例如由高频给药引起的累积毒性及其自​​身毒性),并且还限制了它们的临床用途。因此,此类生物碱的药物递送方面的发展对于改善其类药物性质并因此改善临床治疗效率具有重要意义。策略,包括(i)通过脂质体的特异性递送; (ii)通过纳米颗粒,凝胶和乳液的持续递送; (iii)经核糖体,固体脂质纳米颗粒和渗透促进剂的透皮递送可改善有问题的中药生物碱的药代动力学和理化特性,降低其不良作用,从而提高其疗效。在这篇综述中,对该领域的最新报告进行了全面总结,旨在为相关读者提供参考。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号